

Evidence dossier - Rubric Capital Management

GetCoattail manager profile: <https://getcoattail.com/manager/rubric-capital-management> | CIK 0001687509 | Rank #40 of 149 tracked managers by reported 13F value.

Background: Founded: 2016 | HQ: New York, New York, United States | Style: Value-oriented long/short equity - deep-value longs with an alpha short book, low net exposure | Key person: David Rosen

Background source: <https://www.insidermonkey.com/hedge-fund/rubric-capital-management/968/>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$10.9B Positions: 87 Top-10 concentration: 46.4% of reported value.

Ticker	Company	Weight	Reported value
TLN	Talen Energy Corp	12.70%	\$1.4B
FTAI	Ftai Aviation Ltd	7.45%	\$812M
VTRS	Viatis Inc	4.98%	\$543M
TEVA	Teva Pharmaceutical Inds Ltd	4.84%	\$528M
GLNG	Golar Lng Ltd	4.20%	\$457M
VST	Vistra Corp	2.61%	\$285M
TAC	Transalta Corp	2.57%	\$280M
FLR	Fluor Corp	2.41%	\$263M
KNSA	Kiniksa Pharmaceuticals Intl	2.35%	\$256M
BGC	Bgc Group Inc	2.33%	\$254M

2. Hypothetical 13F-clone results

Window: 2017-02-03 to 2026-10-02 (39 filings). Cumulative: +202.8% CAGR: +12.15% SPY same window: cumulative +290.7%, CAGR +15.15%. Trailing CAGR - 10Y: n/a, 5Y: +15.88%, 3Y: +25.58%, 1Y: +4.86%. Max drawdown (month-end, approximate): -51.1%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q4	0001144204-17-005799	2017-02-03	31
2017Q1	0001144204-17-023076	2017-04-28	31
2017Q2	0001144204-17-039911	2017-08-02	45
2017Q3	0001144204-17-060561	2017-11-22	2
2017Q4	0001144204-18-008344	2018-02-14	49
2018Q1	0001144204-18-028251	2018-05-14	52
2018Q2	0001144204-18-044230	2018-08-14	41

2018Q3	0001144204-18-059056	2018-11-13	52
2018Q4	0001144204-19-007185	2019-02-13	48
2019Q1	0001144204-19-025170	2019-05-10	59
2019Q2	0001144204-19-039488	2019-08-13	52
2019Q3	0001104659-19-063874	2019-11-14	56
2019Q4	0001104659-20-020840	2020-02-14	44
2020Q1	0001104659-20-061442	2020-05-14	49
2020Q2	0001104659-20-092562	2020-08-10	51
2020Q3	0001104659-20-124794	2020-11-13	64
2020Q4	0001104659-21-022690	2021-02-16	59
2021Q1	0001104659-21-066966	2021-05-14	58
2021Q2	0001104659-21-105058	2021-08-13	56
2021Q3	0001104659-21-138188	2021-11-12	55
2021Q4	0001104659-22-021742	2022-02-14	68
2022Q1	0001104659-22-060220	2022-05-13	70
2022Q2	0001104659-22-090772	2022-08-15	88
2022Q3	0001104659-22-118097	2022-11-14	87
2022Q4	0001104659-23-018545	2023-02-10	94
2023Q1	0001104659-23-059698	2023-05-12	70
2023Q2	0001104659-23-090569	2023-08-11	61
2023Q3	0001104659-23-118477	2023-11-15	59
2023Q4	0001104659-24-019871	2024-02-13	56
2024Q1	0001104659-24-059724	2024-05-10	67
2024Q2	0001104659-24-088995	2024-08-13	66
2024Q3	0001104659-24-117768	2024-11-13	63
2024Q4	0001104659-25-014131	2025-02-14	66
2025Q1	0001104659-25-048481	2025-05-14	64
2025Q2	0001104659-25-078662	2025-08-14	62
2025Q3	0001104659-25-112706	2025-11-14	69
2025Q4	0001104659-26-015172	2026-02-13	75
2026Q1	0001104659-26-062466	2026-05-15	81
2026Q2	0001104659-26-097098	2026-08-14	86

4. Coverage and adjustments

Price coverage at the latest filing: 60.6% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.